Tariff Uncertainty and Healthcare Sector Performance.
ByAinvest
Wednesday, Jul 16, 2025 4:21 pm ET1min read
ASML--
ASML's CEO, Christophe Fouquet, stated that while the company continues to prepare for growth in 2026, it cannot confirm it at this stage due to increasing uncertainty driven by macro-economic and geopolitical developments [1]. The company's forecast for third-quarter net sales was between €7.4 billion and €7.9 billion, below the average analyst estimate of €8.2 billion [1].
Meanwhile, Johnson & Johnson shares surged after halving its expectations for tariff-related costs in 2025 and raising its full-year sales and profit forecast. The healthcare giant's shares rose by 6.5% on Wednesday, following the announcement [3].
Johnson & Johnson attributed the reduction in tariff-related costs to the Trump administration's pause on China levies and other duties. The company now expects about $200 million in tariff-related costs this year, down from a previous estimate of about $400 million [3]. J&J's Chief Financial Officer, Joe Wolk, noted that the company was able to absorb those costs and still raise its profit outlook [3].
The healthcare sector has been underperforming, but J&J's strong results present a value-priced leader in the industry. The company beat Wall Street expectations for the second quarter, posting adjusted earnings of $2.29 billion, up from $1.58 billion a year earlier [3].
References:
[1] https://finance.yahoo.com/news/asml-walks-back-2026-growth-061702879.html
[3] https://www.marketscreener.com/quote/stock/JOHNSON-JOHNSON-4832/news/Johnson-Johnson-lifts-2025-forecast-halves-tariff-cost-outlook-50522966/
JNJ--
ASML warned it may not achieve revenue growth in 2026 due to uncertainty surrounding US tariffs. Meanwhile, Johnson & Johnson shares surged after halving its tariff-related costs and raising its full-year sales and profit forecast. The healthcare sector has been underperforming, but J&J's strong results present a value-priced leader in the industry.
ASML Holding NV, the world's leading supplier of chip-making equipment, has warned that it may not achieve revenue growth in 2026 due to uncertainty surrounding US tariffs. The company's shares fell by as much as 11% on Wednesday, reaching a low of €630.70 in Amsterdam, following the announcement [1].ASML's CEO, Christophe Fouquet, stated that while the company continues to prepare for growth in 2026, it cannot confirm it at this stage due to increasing uncertainty driven by macro-economic and geopolitical developments [1]. The company's forecast for third-quarter net sales was between €7.4 billion and €7.9 billion, below the average analyst estimate of €8.2 billion [1].
Meanwhile, Johnson & Johnson shares surged after halving its expectations for tariff-related costs in 2025 and raising its full-year sales and profit forecast. The healthcare giant's shares rose by 6.5% on Wednesday, following the announcement [3].
Johnson & Johnson attributed the reduction in tariff-related costs to the Trump administration's pause on China levies and other duties. The company now expects about $200 million in tariff-related costs this year, down from a previous estimate of about $400 million [3]. J&J's Chief Financial Officer, Joe Wolk, noted that the company was able to absorb those costs and still raise its profit outlook [3].
The healthcare sector has been underperforming, but J&J's strong results present a value-priced leader in the industry. The company beat Wall Street expectations for the second quarter, posting adjusted earnings of $2.29 billion, up from $1.58 billion a year earlier [3].
References:
[1] https://finance.yahoo.com/news/asml-walks-back-2026-growth-061702879.html
[3] https://www.marketscreener.com/quote/stock/JOHNSON-JOHNSON-4832/news/Johnson-Johnson-lifts-2025-forecast-halves-tariff-cost-outlook-50522966/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet